A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme

Trial Profile

A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2014 Primary endpoint 'Progression-free-survival-rate' has not been met according to the results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 01 May 2012 Planned end date changed from 1 May 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top